Eli Lilly has entered into a multi-target partnership with Sosei Group to discover, develop and commercialize compounds targeting novel G protein-coupled receptor (GPCR) targets in diabetes and metabolic diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,